CytomX Therapeutics Inc
6C1
Company Profile
Business description
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Contact
151 Oyster Point Boulevard
Suite 400
South San FranciscoCA94080
USAT: +1 650 515-3185
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
122
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,506.80 | 41.80 | 0.49% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,811.75 | 188.43 | 0.96% |
| NASDAQ | 19,280.79 | 30.00 | -0.16% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,038.86 | 71.88 | -0.55% |
| S&P 500 | 5,868.55 | 13.08 | -0.22% |
| S&P/ASX 200 | 8,243.30 | 42.10 | 0.51% |
| SSE Composite Index | 3,257.52 | 5.04 | -0.15% |